Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing’s Syndrome

Alexandria D. McDow, MD¹, Anju Gurung, MD¹, Rama Poola, MD¹, Carmel Fratianni, MD¹, Marc Garfinkel, MD¹, and Michael G. Jakoby IV, MD/MA¹

Abstract
The hallmark manifestations of Cushing’s syndrome (CS) are well known, but hypercoagulability is perhaps least recognized. Patients with CS are at increased risk of both spontaneous and postoperative thromboembolism, with the significant majority of events occurring in the lower extremity and pulmonary venous circulations. We present a case of portal vein thrombosis (PVT) occurring in the setting of newly diagnosed CS due to a left adrenal adenoma. Factor VIII activity was approximately 2.5-fold elevated, a known mechanism by which hypercortisolism predisposes to venous thrombosis. Acute abdominal pain and fever responded well to unfractionated heparin and parenteral antibiotics, and CS was eventually cured by left adrenalectomy. No thromboembolic events have occurred since surgery. PVT is uncommon and usually occurs as a complication of primary or secondary hepatobiliary malignancies and cirrhosis. To the best of our knowledge, this is just the second reported case of PVT due to CS and the first published in the English language literature.

Keywords
portal vein thrombosis, hypercoagulability, hypercortisolism, Cushing’s syndrome

Introduction
Cushing’s syndrome (CS) is caused by chronic exposure to excess glucocorticoid, with endogenous CS due to elevated levels of cortisol. Endogenous CS may be caused by corticotropin adenomas in the pituitary (Cushing’s disease), ectopic corticotropin (ACTH) production by peripheral tumors of neuroendocrine origin (eg, small cell carcinoma), or adrenal adenomas and carcinomas that autonomously overproduce cortisol. The adverse effects of excess cortisol are wide ranging and include centripetal obesity, sarcopenia, insulin resistance, hypertension, immunosuppression, and accelerated bone loss. Endogenous CS patients have a 2-fold higher rate of mortality than unaffected individuals that persists even after successful treatment.¹

An important but less commonly recognized complication of hypercortisolism is hypercoagulability and venous thromboembolism (VTE). CS patients have an increased risk of both spontaneous and postoperative VTE. In a systematic review of 15 patient series, the incidence of spontaneous or postoperative VTE for CS patients was approximately 10-fold higher than the estimated incidence in an age- and gender-matched control population.² A subsequent multicenter cohort study documented a 4% preoperative VTE rate for CS patients, and 3.4% of Cushing’s disease patients experienced VTE after transsphenoidal surgery (TSS) despite postoperative thromboprophylaxis with low-molecular-weight heparin.³ No VTE occurred among control patients undergoing TSS for nonfunctional pituitary adenomas.³

We present an unusual case of portal vein thrombosis (PVT) complicating CS caused by an adrenal adenoma. A PubMed search with the terms “portal vein thrombosis” and “Cushing’s syndrome” yielded only one brief French language case report⁴; to the best of our knowledge, this is only the second reported case of PVT due to CS and the first published in the English language case report.

Case Presentation
A 61-year-old female presented to the hospital for evaluation of right upper quadrant abdominal pain. The patient was febrile, and initial laboratories revealed leukocytosis (19,150/mm³, 4.00-10.80), mild elevation of alkaline phosphatase.

¹Southern Illinois University, Springfield, IL, USA

Received January 8, 2017. Revised March 3, 2017. Accepted March 9, 2017.

Corresponding Author:
Michael Jakoby IV, MD/MA, Southern Illinois University School of Medicine, Division of Endocrinology, 751 N Rutledge St, Suite 0400, Springfield, IL 62794, USA.
Email: mjakoby@siumed.edu

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
level (165 units/L, 50-130), and hypokalemia (2.9 mmol/L, 3.5-5.0). Neither cholecintigraphy nor right upper quadrant abdominal ultrasound showed evidence of cholecystitis, but the left portal vein was found to be occluded by ultrasonography. No sonographic features of cirrhosis (eg, increased echogenicity, significant nodularity, or right hepatic lobe atrophy) were observed. Left PVT was subsequently confirmed by computed tomography (CT; Figure 1A). Abdominal CT also revealed an incidental 3.8 × 3.2 cm left adrenal mass with radiographic features favoring adenoma including regular borders and homogeneous, low-density attenuation (~9 Houndsfield units) on noncontrast images (Figure 1B). No lower extremity venous thrombi were detected by ultrasound venous Doppler imaging.

Endocrinology consultation was obtained due to discovery of the left adrenal mass. CS was suspected due to truncal obesity, prominent dorsal cervical fat pad, moon facies, plethora, and hirsutism on examination (Figure 1C) and hypokalemia at initial presentation. Hypercortisolism was confirmed by multiple diagnostic tests including overnight dexamethasone suppression test, midnight plasma cortisol, midnight salivary cortisol, and 24-hour urine free cortisol (Table 1). Morning ACTH level was <10 pg/mL (Table 1), indicating ACTH-independent hypercortisolism.

The patient also underwent a simultaneous hypercoagulability workup. Evaluation for procoagulant antibodies (eg, antiphospholipid antibodies); deficiencies of protein C, protein S, and antithrombin III; prothrombin G2021A mutation; and activated protein C resistance was unremarkable. Factor VIII activity was significantly elevated at 365% (50% to 149%).

PVT due to hypercoagulability caused by a cortisol hypersecreting left adrenal adenoma was diagnosed. Fever was felt to be a sign of pylephlebitis, so the patient was managed.
Glucocorticoid excess also increases plasminogen in CS, particularly factor VIII and von Willebrand factor. VIII level was significantly elevated (365%). Levels above fibrinolytic capacity predispose to venous thrombosis. A combination of increased coagulation factors and decreased activator inhibitor type 1 (PAI-1) levels and activity. The function, including endothelin-1, homocysteine, osteoprotegerin, and vascular endothelial growth factor are elevated in CS, and endothelial dependent vasodilatation is also measurably impaired. Multiple coagulation factors are increased in CS, particularly factor VIII and von Willebrand factor (vWF). Glucocorticoid excess also increases plasminogen activator inhibitor type 1 (PAI-1) levels and activity. The combination of increased coagulation factors and decreased fibrinolytic capacity predisposes to venous thrombosis. Neither vWF nor PAI-1 was measured in this case, but factor VIII level was significantly elevated (365%). Levels above 160% are associated with a 4-fold increased risk of VTE. Some CS patients develop a secondary polycythemia that may cause venous stasis from hyperviscosity, and decreased activity, especially immobilization after surgery, also predisposes to venous stasis and thrombosis.

Our patient’s case is unusual because most cases of CS-associated VTE occur in the lower extremities and PVT is rare. In a large series of 307 patients with CS, 29 (9.3%) experienced VTE, and the vast majority of patients (27/29, 93%) were diagnosed with deep vein thrombosis (DVT). Ten of the 27 patients with DVT also experienced fatal or nonfatal pulmonary embolism (PE), and another patient experienced a fatal PE without reported DVT. A recently published review of 13 patient series and over 1300 cases of CS found a similar rate of VTE (8.9%), with almost all patients experiencing lower extremity DVT and/or PE. Slightly more cases of VTE occurred after surgery rather than spontaneously.

An autopsy series from Malmö, Sweden, with nearly 24000 patients found a 1% cumulative incidence of PVT. Secondary hepatobiliary malignancy, cirrhosis, primary hepatobiliary malignancy, abdominal infections or inflammatory conditions, and myeloproliferative disorders were the major etiologies of PVT in descending order of frequency and collectively accounted for 86% of PVT cases. No cases of PVT associated with CS were reported in the Swedish autopsy series, and PubMed searches linking the terms “Cushing’s syndrome,” “hypercortisolemia,” “hypercortisolism,” “cortisol,” and “portal vein thrombosis” yielded only the single French language case report from Tunisia previously noted. There appear to be at least 2 key reasons why CS is less likely to cause thrombosis in the portal venous circulation than the lower extremity venous circulation: (1) hypercortisolemia does not cause the thrombophilia states—factor V Leiden mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, and antiphospholipid antibodies—that are most commonly associated with PVT and (2) blood flow rate through the portal venous circulation measured by duplex ultrasonography (DUS) is 2- to 20-fold higher than DUS measured lower extremity venous blood flow depending on the vein evaluated.

Perioperative thromboprophylaxis appears to reduce the risk of postoperative VTE for CS patients, though relatively little is published on the topic and there are no clear recommendations regarding the type or duration of anticoagulation. Boscaro and colleagues compared the rate of VTE in 75 patients who did not receive postoperative anticoagulation (group 1) to 232 patients who received unfractionated heparin for at least 2 weeks followed by warfarin for at least 4 months (group 2). VTE rate was reduced from 20% in group 1 to 6% in group 2, and survival analysis demonstrated a significantly lower rate of morbidity and mortality from thromboembolic events in group 2. Recently, Barbot and colleagues compared 2 groups of Cushing’s disease patients undergoing TSS; group A received fractionated heparin from postoperative day 1 to discharge or a total of 14 days plus glucocorticoid replacement, and group B was managed with 30 days of fractionated heparin, compression stockings, early ambulation, and omission of glucocorticoids. There were no VTE events in group B compared to 3 in group A, though the difference was not quite statistically significant. The hypercoagulable state of CS may persist well beyond the time that cortisol levels return to normal. Markers of hemostasis and fibrinolysis failed to change significantly after 80 days in a group of patients with Cushing’s disease managed medically to biochemical remission of hypercortisolemia as indicated by normalization of 24-hour urine-free cortisol. Though PVT was our patient’s initial thromboembolic event, she was managed with a 6-month course of warfarin due to occurrence of VTE in the setting of CS.

### Table 1. Biochemical Evaluation for Cushing’s Syndrome.

| Parameter                              | Result | Reference Range |
|----------------------------------------|--------|-----------------|
| Midnight plasma cortisol (µg/dL)       | 10.5   | <7.5            |
| Midnight salivary cortisol (µg/dL)     | 550    | <100            |
| 24-Hour urine free cortisol (µg)       | 146    | 3.5-45          |
| 8 AM ACTH (pg/mL)                      | 7.2    | 10-60           |

Increased risk of VTE in CS appears to be due cortisol-induced changes to all 3 components of Virchow’s triad—vascular endothelial injury, hypercoagulable state, and venous stasis. Several humoral markers of endothelial dysfunction, including endothelin-1, homocysteine, osteoprotegerin, and vascular endothelial growth factor are elevated in CS, and endothelial dependent vasodilatation is also measurably impaired. Multiple coagulation factors are increased in CS, particularly factor VIII and von Willebrand factor (vWF). Glucocorticoid excess also increases plasminogen activator inhibitor type 1 (PAI-1) levels and activity. The combination of increased coagulation factors and decreased fibrinolytic capacity predisposes to venous thrombosis. Neither vWF nor PAI-1 was measured in this case, but factor VIII level was significantly elevated (365%). Levels above 160% are associated with a 4-fold increased risk of VTE. Some CS patients develop a secondary polycythemia that may cause venous stasis from hyperviscosity, and decreased activity, especially immobilization after surgery, also predisposes to venous stasis and thrombosis.

Our patient’s case is unusual because most cases of CS-associated VTE occur in the lower extremities and PVT is rare. In a large series of 307 patients with CS, 29 (9.3%) experienced VTE, and the vast majority of patients (27/29, 93%) were diagnosed with deep vein thrombosis (DVT). Ten of the 27 patients with DVT also experienced fatal or nonfatal pulmonary embolism (PE), and another patient experienced a fatal PE without reported DVT. A recently published review of 13 patient series and over 1300 cases of CS found a similar rate of VTE (8.9%), with almost all patients experiencing lower extremity DVT and/or PE. Slightly more cases of VTE occurred after surgery rather than spontaneously.

An autopsy series from Malmö, Sweden, with nearly 24000 patients found a 1% cumulative incidence of PVT. Secondary hepatobiliary malignancy, cirrhosis, primary hepatobiliary malignancy, abdominal infections or inflammatory conditions, and myeloproliferative disorders were the major etiologies of PVT in descending order of frequency and collectively accounted for 86% of PVT cases. No cases of PVT associated with CS were reported in the Swedish autopsy series, and PubMed searches linking the terms “Cushing’s syndrome,” “hypercortisolemia,” “hypercortisolism,” “cortisol,” and “portal vein thrombosis” yielded only the single French language case report from Tunisia previously noted. There appear to be at least 2 key reasons why CS is less likely to cause thrombosis in the portal venous circulation than the lower extremity venous circulation: (1) hypercortisolemia does not cause the thrombophilia states—factor V Leiden mutation, protein C deficiency, protein S deficiency, antithrombin deficiency, and antiphospholipid antibodies—that are most commonly associated with PVT and (2) blood flow rate through the portal venous circulation measured by duplex ultrasonography (DUS) is 2- to 20-fold higher than DUS measured lower extremity venous blood flow depending on the vein evaluated.

Perioperative thromboprophylaxis appears to reduce the risk of postoperative VTE for CS patients, though relatively little is published on the topic and there are no clear recommendations regarding the type or duration of anticoagulation. Boscaro and colleagues compared the rate of VTE in 75 patients who did not receive postoperative anticoagulation (group 1) to 232 patients who received unfractionated heparin for at least 2 weeks followed by warfarin for at least 4 months (group 2). VTE rate was reduced from 20% in group 1 to 6% in group 2, and survival analysis demonstrated a significantly lower rate of morbidity and mortality from thromboembolic events in group 2. Recently, Barbot and colleagues compared 2 groups of Cushing’s disease patients undergoing TSS; group A received fractionated heparin from postoperative day 1 to discharge or a total of 14 days plus glucocorticoid replacement, and group B was managed with 30 days of fractionated heparin, compression stockings, early ambulation, and omission of glucocorticoids. There were no VTE events in group B compared to 3 in group A, though the difference was not quite statistically significant. The hypercoagulable state of CS may persist well beyond the time that cortisol levels return to normal. Markers of hemostasis and fibrinolysis failed to change significantly after 80 days in a group of patients with Cushing’s disease managed medically to biochemical remission of hypercortisolemia as indicated by normalization of 24-hour urine-free cortisol. Though PVT was our patient’s initial thromboembolic event, she was managed with a 6-month course of warfarin due to occurrence of VTE in the setting of CS.
Elevated serum cortisol induces changes in hemostatic and fibrinolytic pathways that create a prothrombotic state, and this manifests clinically as increased risks of spontaneous and postoperative VTE. Lower extremity DVT and PE account for the significant majority of thrombotic events in CS patients. We present a case of CS due to an adrenal adenoma as the etiology of PVT, a rare clinical event that mostly occurs as a complication of cirrhosis or hepatobiliary malignancy. This appears to be only the second reported case of PVT complicating CS and the first in the English language peer-reviewed literature. The patient responded well to initial treatment with unfractionated heparin and antimicrobial therapy followed by laparoscopic adrenalectomy and a 6-month course of warfarin. Prolonged anticoagulation for patients with CS and VTE appears advisable given potential persistence of a hypercoagulable state beyond initial resolution of hypercortisolemia. Though lower extremity DVT and PE are the most likely complications of hypercoagulability in CS, this case illustrates that CS also has the potential to cause PVT.

Authors’ Note
This case was presented as poster FRI 465 at the Endocrine Society’s 98th Annual Meeting and Expo, April 1-4, 2016, Boston, MA.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98:2277-2284.
2. Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94:2743-2750.
3. Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96:3525-3532.
4. Chebbi W, Berriche O. Portal vein thrombosis revealing a Cushing syndrome in the elderly [in French]. Pan Afr Med J. 2014;18:186.
5. Dickson BC. Venous thrombosis: on the history of Virchow’s triad. Unv Toronto Med J. 2004;81:166-171.
6. Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol. 2003;149:549-553.
7. Terzolo M, Allasino B, Bosio S, et al. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2004;89:3745-3751.
8. Dovio A, Allasino B, Palmas E, et al. Increased osteoprotegerin levels in Cushing’s syndrome are associated with an adverse cardiovascular risk profile. J Clin Endocrinol Metab. 2007;92:1803-1808.
9. Zacharieva S, Atanassova I, Nachev E, et al. Markers of vascular function in hypertension due to Cushing’s syndrome. Horm Metab Res. 2005;37:36-39.
10. Baykan M, Erem C, Gedikli O, et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing’s syndrome. Endocrine. 2007;31:300-304.
11. Miljic P, Miljic D, Cain JW, Korbonits M, Popovic V. Pathogenesis of vascular complications in Cushing’s syndrome. Hormones (Athens). 2012;11:21-30.
12. Erem C, Nuhoglu I, Yilmaz M, et al. Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest. 2009;32:169-174.
13. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab. 2002;87:3662-3666.
14. Coelho MC, Santos CV, Vieira Neto L, Gadella MR. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol. 2015;173:M11-M21.
15. Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12:2115-2119.
16. DeLeve LD, Valla DC, Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729-1764.
17. Costa JD, Leão ARS, Santos JEM, et al. Measurement of portal vein thrombosis: reproducibility of ultrasound scan in the assessment of volume flow in the veins of the lower extremities. J Vasc Surg. 2008;41:219-224.
18. Ogawa T, Lurie F, Kistner RL, Eklof B, Tabrah FL. Reproducibility of ultrasound scan in the assessment of volume flow in the veins of the lower extremities. J Vasc Surg. 2002;35:527-531.
19. Barbot M, Daidone V, Zilio M, et al. Perioperative thrombo-prophylaxis in Cushing’s disease: what we did and what we are doing? Pituitary. 2015;18:487-493.
20. van der Pas R, de Bruin C, Leebeek FW, et al. The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012;97:1303-1310.